Summer 2025, Fall 2025

Vertex Fall 2025 Co-op

Engineering

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$20 - $35/hr

+ Bonus + Equity Awards

No H1B Sponsorship

Boston, MA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
SolidWorks
Requirements
  • Majors in the following backgrounds: Mechanical Engineering, Bioengineering, Chemical Engineering, Biomedical Engineering, Biotechnology, Pharmaceutical Sciences, Biology with heavy automation work, or a related field of study.
  • Experience generating 3D solid body models in SolidWorks
  • Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization.
  • Candidate must be enrolled in an advanced degree program if graduating before July 2025
  • Candidate must be available to work full-time, 40 hours per week from July - December 2025
Responsibilities
  • Supporting device related activities supporting various device programs, including prototyping and sample preparation/build to perform mechanical testing on the device, fixture design/redesign to improve the experimental apparatus, and design of experiment to support proof-of-concept and optimization studies.
  • Taking ownership of an internship project and contributing to the development of commercially relevant manufacturing processes.
  • Developing modeling for process analytical technology (PAT), providing solutions to urgent issues in analytical method life-cycle management, and/or advancing key product and process understanding.
  • Learning bioprocessing of viral vectors and assisting scientific staff in the process development and production of viral vectors.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • EU approval for expanded cystic fibrosis treatment label boosts market penetration in Europe.
  • Partnership with Arbor Biotechnologies positions Vertex at the forefront of innovative treatments.
  • Recent investments indicate strong investor confidence in Vertex's growth potential.

What critics are saying

  • Recent layoffs suggest financial or strategic challenges impacting operational capabilities.
  • Discontinuation of diabetes asset indicates difficulty diversifying beyond cystic fibrosis.
  • Reliance on key products like ivacaftor makes Vertex vulnerable to market fluctuations.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic partnerships for drug development.
  • Vertex's collaboration with Arbor Biotechnologies advances novel ex vivo engineered cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Pharmalive
Jun 11th, 2025
After axing diabetes asset, Vertex lays off 140 staff

After axing diabetes asset, Vertex lays off 140 staff.

PBN
Jun 10th, 2025
Vertex Pharmaceuticals to lay off 125 R.I. employees

PROVIDENCE - Vertex Pharmaceuticals Inc. is laying off 125 people in Rhode Island, according to a WARN notice filed with the R.I. Department of Labor and Training on June 8.

Buniversity
May 1st, 2025
VERTEX upset Grayhound for spot at BLAST Showdown

VERTEX locked in a first-place finish at Fortress OCE Masters Fall 2022 Finals in Melbourne to qualify for BLAST Premier Fall Showdown.

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.